Home/Protocols/BPC-157
Protocol Reference
HEALING

BPC-157 (10 mg vial)

Once daily subcutaneous protocol for tissue-repair research.

BPC-157 is a synthetic pentadecapeptide derived from a protective protein in gastric juice, with an unusually consistent rodent literature across tendon, muscle, gut and vessel injury models and no human trials at all. The protocol below is the community-standard once-daily subcutaneous approach, injected near the problem area when practical.

Quick answer: at the standard 10 mg + 1 mL reconstitution, a 600 mcg dose of BPC-157 draws 6 units (0.06 mL) on a U-100 insulin syringe, once daily subcutaneous.

Get BPC-157 → code PEPDOSE

Category
Healing & Repair
Common vials
10, 20 mg
Half-life
Not established in humans
Route in the literature
Subcutaneous or oral in animal work

Protocol overview

Research area
Tissue-healing and cytoprotective models
Evidence
Animal and cell studies only; no human trials
Dosing in the literature
10 ng/kg to 10 μg/kg once daily in rodent models
Reconstitution
1 to 2 mL per 10 mg vial gives 10 or 5 mg/mL
Storage
Lyophilized cold and dark; reconstituted at 2 to 8 °C

Dosing & reconstitution

Community-reported ranges. These are the amounts commonly reported in user communities and vendor protocols, not from controlled human trials. They are listed here because they are what most people reference in practice.

Frequency: Once daily subcutaneous
Typical duration: 8-12 weeks

Reconstitution: 10 mg vial + 1 mL bacteriostatic water = 10 mg/mL. Units below are for a U-100 insulin syringe at this concentration.

PhaseDoseUnits per injection
Weeks 1-2200 mcg2 units (0.02 mL)
Weeks 3-4400 mcg4 units (0.04 mL)
Weeks 5-8+600 mcg6 units (0.06 mL)

Units = (dose ÷ concentration) × 100 on a U-100 syringe. Change the vial size or water volume and the calculator redoes all of this for you.

Track this protocol → Free account · log doses, rotate sites, never lose your history

BPC-157 dosing — what the literature actually supports

Animal data only. This is the single most important thing to know about BPC-157: despite how widely it is discussed, there are no published human clinical trials establishing a dose. The entire evidence base is rodent work, where amounts are given in micrograms per kilogram of rat and administered by routes that do not map onto human use. Any human schedule you see quoted — including the widely circulated microgram-per-kilogram figures — is an extrapolation somebody performed, not a measured human amount from a trial.

We publish a schedule when there is a citable human source and we say so when there is not. Filling this space with a number nobody measured would make the page look more complete and be worth less than nothing to you.

What the published studies actually administered

These are the amounts that appear in the actual published work, reported as published. They are animal doses and cell-culture concentrations, not human protocols.

WorkAmount usedRouteContext
Rodent injury models (Sikiric group, dozens of papers)10 ng/kg or 10 μg/kg, typically once dailyIntraperitoneal, intragastric, or topical by modelThe two canonical doses repeated across the gut, tendon, muscle and vessel studies
Tendon fibroblast work (Chang 2011)ng/mL to μg/mL in culture mediumIn vitroConcentrations in a dish, not doses in a body
About the figures you see elsewhere: the 200 to 800 mcg daily "protocols" circulating on retailer and community pages trace back to scaling the rat 10 μg/kg dose to human bodyweight. That conversion assumes allometric scaling holds, that the injection route matches the study route, and that rat and human pharmacokinetics are interchangeable. None of those have been tested, which is why we report the extrapolation as an extrapolation instead of printing it as a schedule.

Reconstitution and measurement

This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for BPC-157: 10, 20 mg.

  1. Wipe the stoppers of both vials with an alcohol swab and let them dry.
  2. Draw the bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the peptide vial — never straight onto the powder.
  3. Swirl gently until the solution is clear. Do not shake; foaming and agitation damage peptides.
  4. Label the vial with the date and concentration, and refrigerate at 2–8 °C protected from light.

Worked example at the calculator defaults: 10 mg + 2 mL of bacteriostatic water = 5 mg/mL, so on a U-100 insulin syringe 1 unit = 50 mcg of BPC-157. Change either input and the calculator redoes this for you.

Open the BPC-157 calculator → Unit converter

Storage and stability

Dry powder
Cold, dark and dry. Lyophilized peptide is the stable form — keep it that way until you intend to use it.
After reconstitution
Refrigerate at 2–8 °C, protect from light, and plan around a limited window. Do not freeze a reconstituted vial — freeze-thaw damages peptides.
Mixing
Run bacteriostatic water down the inside wall of the vial rather than onto the powder, then swirl. Never shake.
Inspect before use
A clear solution is expected. Cloudiness or particles mean discard, not use.

Full storage guide → · Cloudy solution?

Supplies math

Whatever amounts your research uses, the planning arithmetic is the same. The calculator runs all of this per compound.

Vials
Doses per vial = vial size in mg divided by your per-dose amount in mg. The calculator on this page runs that arithmetic for any vial size and amount you enter.
Syringes
One sterile U-100 insulin syringe per injection, plus roughly 10% spares for bent tips and mis-draws. Daily protocols run 30 or 31 per month.
Bacteriostatic water
1 to 3 mL per vial reconstituted. A single 10 mL bottle covers 3 to 10 vials, so one bottle usually outlasts several vials.
Alcohol swabs
Two per injection: one for the vial stopper, one for the site. A 100-count box covers about 7 weeks of daily work.

Supplies by protocol length

Based on the maintenance dose above (600 mcg, once daily subcutaneous) and a 10 mg vial reconstituted with 1 mL.

DurationInjectionsVialsSyringesBac waterSwabs
8 weeks564 x 10 mg621 x 10 mL112
12 weeks846 x 10 mg931 x 10 mL168
16 weeks1127 x 10 mg1241 x 10 mL224

Syringe count includes ~10% spares. Swabs = 2 per injection (stopper + site). Vial count assumes the full maintenance dose for the entire duration.

Important notes

Practical considerations for consistency and safety.

  • Use a new sterile insulin syringe for each injection and dispose in a proper sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and avoid lipohypertrophy.
  • Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
  • Administer at the same time each day for consistent levels. Setting a daily reminder helps maintain the schedule.
  • This compound lacks controlled human safety data. Start with the lowest reported amount and increase gradually while monitoring for any adverse reactions.
  • The 10 mg vial size is standard for this compound. Reconstitute with 1 mL bacteriostatic water for a convenient concentration.

How BPC-157 works

A synthetic pentadecapeptide derived from a sequence found in human gastric juice. Rodent work reports accelerated tendon, muscle and gut healing, with effects on angiogenesis and nitric-oxide signalling proposed as mechanisms.

Benefits & side effects

Potential benefits

  • Consistently accelerates healing in rodent injury models
  • Anti-inflammatory and cytoprotective in preclinical work
  • Wide therapeutic window reported in animal studies
  • Supports tendon, muscle, gut and vessel healing in models

Possible side effects

  • No human safety data from controlled trials
  • Injection site reactions
  • Added to sport prohibited monitoring in 2022
  • All safety information is from animal models

This list reflects published literature and community reports. Individual responses vary. Not medical advice.

Bloodwork worth tracking

The community-standard practice is a baseline panel before starting, a recheck 8 to 12 weeks in, and another after time off. For BPC-157, the markers most worth watching:

CMPCBC

Typical time off: 2-4 wks

Lab panels are how a research protocol stays honest: numbers move before symptoms do. Interpretation belongs with a clinician. Not medical advice.

Lifestyle factors

None of the literature above was run on a background of poor sleep and no protein. These variables move outcomes more reliably than any compound on this site.

  • Tendon and muscle models in the literature pair the compound with controlled loading — tissue adapts to progressive load, and no rodent study used bed rest as the protocol.
  • Protein intake and overall energy availability set the ceiling on any repair process being studied.
  • Sleep is when most tissue-repair signalling happens; it is the cheapest variable in the whole model.
  • For an actual injury, a qualified clinician and a rehab plan are the intervention with human evidence behind them.

Subcutaneous technique and practical notes

General best practice from clinical injection guidance — the same fundamentals nurses are taught, none of it specific to any compound.

Fresh sterile syringe, every time
Reusing needles dulls the tip, hurts more, and is the easiest contamination route. Dispose of used syringes in a sharps container, not the bin.
Rotate sites
Abdomen (5 cm clear of the navel), thighs, upper arms. Rotating systematically prevents localised irritation and lipohypertrophy.
Slow and steady
Pinch a skinfold, insert at 45–90°, inject slowly, and wait a few seconds before withdrawing. Subcutaneous injections are not aspirated.
Write it down
Log the date, amount and site. A record is the only way to keep any research protocol consistent — and the first thing to review if anything looks off.

References

  • Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011. — find on PubMed
  • Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011. — find on PubMed
  • Seiwerth S, et al. BPC 157 and blood vessels. Current Pharmaceutical Design, 2014. — find on PubMed
  • Vukojevic J, et al. Rat inferior caval vein occlusion and BPC 157 (vascular recruitment). Vascular Pharmacology, 2018. — find on PubMed

Broader literature searches:

Quick answers

How many syringe units is a 600 mcg dose of BPC-157?

At the standard reconstitution of 10 mg with 1 mL bacteriostatic water (10 mg/mL), a 600 mcg dose draws 6 units (0.06 mL) on a U-100 insulin syringe.

How do you reconstitute BPC-157?

Add 1 mL of bacteriostatic water to the 10 mg vial for 10 mg/mL. Inject the water slowly down the inside wall of the vial, swirl gently without shaking, and refrigerate at 2 to 8 °C after mixing.

How long does a 10 mg vial of BPC-157 last?

About 16 maintenance doses of 600 mcg, roughly 2.3 weeks at once daily subcutaneous.

Does BPC-157 have human trial data?

No. The evidence base is animal and cell studies; the practical dosing shown is community convention, and the page labels it that way.

How does BPC-157 work?

A synthetic pentadecapeptide derived from a sequence found in human gastric juice. Rodent work reports accelerated tendon, muscle and gut healing, with effects on angiogenesis and nitric-oxide signalling proposed as mechanisms.

Sourcing BPC-157

Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.

BPC-157 at Summit Research Supply → Grade a COA first

Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.

For laboratory research use only. This page documents what the published literature reports about BPC-157. It is not a recommendation, not a treatment plan, and not medical advice. Compounds referenced are sold strictly as research chemicals and are not for human or veterinary use. Some supplier links are affiliate links and may earn us a commission. This never affects tier placement or review conclusions.
Summit Research Supply
Summit Research Supply — COA-verified research peptidesThird-party tested · U.S. fulfillment · new researchers save 10%
Shop →